Skip to contentI
Inovio Pharmaceuticals, Inc.
I
INOInovio Pharmaceuticals, Inc. Q2 2017 · 10-Q
Revenue$20.41M$20.41M+229.0% vs Q2 2016 Net Income-$9.48M-$9.48MN/M vs Q2 2016 EPS Diluted-$0.13-$0.13N/M vs Q2 2016 Operating Income-$9,635,733N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inovio Pharmaceuticals, Inc. · CIK 1055726 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$21,758,421N/M Margins · derivedOperating margin-47.2%+246.6 pt vs Q2 2016
Net margin-46.4%+255.1 pt vs Q2 2016
ended Jun 30, 2017 · filed Aug 8, 2017 · 39 d after period end